GCG and obesity disorder: Partially mirroring current findings, the GLP-1 agonist liraglutide caused no significant changes in self-reported hedonic responses to food despite causing significant weight loss, significant increases in self-reported fullness, and decreases in self-reported hunger in a randomized controlled trial for obesity (Tronieri et al., 2020).